Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONQUEST platform study in systemic sclerosis-associated interstitial lung disease
jRCT2031240052Phase 2Active, not recruiting
- Sponsor
- Scleroderma Research Foundation, Inc.
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of amlitelimab and nerandomilast in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) (4 arms), sponsored by Scleroderma Research Foundation, Inc. Primary endpoint: Change in forced vital capacity. Started Jul 2024; status: active, not recruiting.
02
Drugs
amlitelimabnerandomilast
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on jRCT2031240052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240052.